REDUCTION IN SERUM IL-6 AFTER VACINATION OF BREAST CANCER PATIENTS WITH TUMOUR-ASSOCIATED ANTIGENS IS RELATED TO ESTROGEN RECEPTOR STATUS

This publication has 28 references indexed in Scilit:

• A phase I clinical trial of immunotherapy with interferon-? gene-modified autologous melanoma cells
  Cancer, 1997
• Considerations for the Clinical Development of Cytokine Gene-Transduced Tumor Cell Vaccines
  Methods, 1997
• Carcinoembryonic antigen as a target for cancer vaccines
  Cancer Immunology, Immunotherapy, 1996
• Tumor antigens and tumor vaccines: Peptides as immunogens
  Seminars in Surgical Oncology, 1996
• Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and Bacillus Calmette-Guèrin: Five-year results of a prospective randomized study
  Cancer, 1996
• Epitope selection and development of peptide based vaccines to treat cancer
  Seminars in Cancer Biology, 1995
• New tumor antigens recognized by T cells
  Current Opinion in Immunology, 1995
• Identification of wild‐type and mutant p53 peptides binding to HLA‐A2 assessed by a peptide loading‐deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay
  European Journal of Immunology, 1994
• Induction of T Cells Specific for the Mutated Segment of Oncogenic P21ras Protein by Immunization In Vivo with the Oncogenic Protein
  Journal of Immunotherapy, 1993
• Presentation of Soluble antigen to human T cells by products of multiple HLA-linked loci: Analysis of antigen presentation by a panel of cloned, autologous, HLA-mutant epstein-barr virus-transformed lymphoblastoid cell lines
  Human Immunology, 1987